Alymsys is a vascular endothelial growth factor inhibitor.
Your search for bevacizumab returned 6 results
Vegzelma is a vascular endothelial growth factor inhibitor.
The approval was based on data demonstrating that the biosimilar product and the reference product were highly similar, and that there were no clinically meaningful differences between the agents.
The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.
The approval was based on data from the SORAYA trial.
Mirvetuximab soravtansine is an antibody-drug conjugate comprised of a FRα-binding antibody, a cleavable linker, and a potent tubulin-targeting agent.